Anti-EMAP II antibody and use thereof
The present invention relates to an anti-EMAP II antibody or an antigen-binding fragment thereof, a nucleic acid molecule for coding the same, or a preparation method thereof. Also, the present invention provides a method for using the anti-EMAP II antibody or the antigen-binding fragment thereof in preventing, treating or diagnosing EMAP II-mediated diseases, for example, TNF-α-mediated disease or Alzheimer's disease. Furthermore, the present invention provides a method for using the anti-EMAP II antibody or the antigen-binding fragment thereof in detecting or quantifying an EMAP II antigen. The antibody of the present invention may exhibit a more improved antigen-binding capacity compared to existing anti-EMAP antibodies and may treat the TNF-α-mediated disease more effectively.
1. An anti-EMAP II (endothelial monocyte activating polypeptide II) antibody or an antigen-binding fragment thereof, comprising a light chain variable region, containing a light chain CDR1 consisting of SEQ ID NO: 7, a light chain CDR2 consisting of SEQ ID NO: 9, and a light chain CDR3 consisting of SEQ ID NO: 11; and a heavy chain variable region, containing a heavy chain CDR1 consisting of SEQ ID NO: 12, a heavy chain CDR2 consisting of SEQ ID NO: 14, and a heavy chain CDR3 consisting of SEQ ID NO: 16.
2. The anti-EMAP II antibody or the antigen-binding fragment thereof according to claim 1 , wherein the antibody comprises a light chain variable region consisting of SEQ ID NO: 3; and a heavy chain variable region consisting of SEQ ID NO: 4.
3. The anti-EMAP II antibody or the antigen-binding fragment thereof according to claim 1 , characterized in that the antibody is a humanized antibody.
4. The anti-EMAP II antibody or the antigen-binding fragment thereof according to claim 1 , wherein the antibody comprises a kappa or human IgG-derived constant region.
5. The anti-EMAP II antibody or the antigen-binding fragment thereof according to claim 1 , characterized in that the antigen binding fragment is Fab, F(ab′), F(ab′)2 or Fv.
6. A nucleic acid molecule for coding the antibody or the antigen-binding fragment thereof according to claim 1 .
7. A recombinant vector comprising the nucleic acid molecule according to claim 6 .
8. A transformed cell comprising the recombinant vector according to claim 7 .
9. A method for preparing an anti-EMAP II antibody or an antigen-binding fragment thereof, comprising a step of expressing the anti-EMAP II antibody or the antigen-binding fragment thereof by culturing the transformed cell according to claim 8 and (ii) a step of isolating the anti-EMAP II antibody or the antigen-binding fragment thereof.
10. A pharmaceutical composition, comprising the anti-EMAP II antibody or the antigen-binding fragment thereof according to claim 1 as an active ingredient.
11. A composition for detecting an EMAP II antigen, comprising the anti-EMAP II antibody or the antigen-binding fragment thereof according to claim 1 as an active ingredient.
12. A kit for detecting an EMAP II antigen, comprising the anti-EMAP II antibody or the antigen-binding fragment thereof according to claim 1 as an active ingredient.
13. A method for detecting an EMAP II antigen in a sample, comprising a step of bringing the anti-EMAP II antibody or the antigen-binding fragment thereof according to claim 1 into contact with the sample.
14. A method for treating EMAP II-mediated disease, including administering a therapeutically effective amount of a composition comprising the anti-EMAP II antibody or the antigen binding fragment thereof according to claim 1 , wherein the EMAP II-mediated disease is rheumatoid arthritis.